TW200640457A - Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes - Google Patents

Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Info

Publication number
TW200640457A
TW200640457A TW095105631A TW95105631A TW200640457A TW 200640457 A TW200640457 A TW 200640457A TW 095105631 A TW095105631 A TW 095105631A TW 95105631 A TW95105631 A TW 95105631A TW 200640457 A TW200640457 A TW 200640457A
Authority
TW
Taiwan
Prior art keywords
diabetes
rimonabant
prevention
preparation
treatment
Prior art date
Application number
TW095105631A
Other languages
English (en)
Chinese (zh)
Inventor
Corinne Hanotin
Pierre Rosenzweig
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW200640457A publication Critical patent/TW200640457A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095105631A 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes TW200640457A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Publications (1)

Publication Number Publication Date
TW200640457A true TW200640457A (en) 2006-12-01

Family

ID=36809538

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095105631A TW200640457A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Country Status (10)

Country Link
JP (1) JP2008530189A (ja)
BR (1) BRPI0608183A2 (ja)
CR (1) CR9293A (ja)
EA (1) EA011618B1 (ja)
FR (2) FR2882264A1 (ja)
IL (1) IL185401A0 (ja)
MA (1) MA29262B1 (ja)
MX (1) MX2007009996A (ja)
TN (1) TNSN07297A1 (ja)
TW (1) TW200640457A (ja)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
FR2882265A1 (fr) 2006-08-25
JP2008530189A (ja) 2008-08-07
MX2007009996A (es) 2007-10-10
MA29262B1 (fr) 2008-02-01
FR2882265B1 (fr) 2009-02-13
EA011618B1 (ru) 2009-04-28
EA200701781A1 (ru) 2007-12-28
TNSN07297A1 (en) 2008-12-31
CR9293A (es) 2007-10-01
BRPI0608183A2 (pt) 2009-11-17
IL185401A0 (en) 2008-08-07
FR2882264A1 (fr) 2006-08-25

Similar Documents

Publication Publication Date Title
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
MY148723A (en) Use of pinolenic acid for the treatment of obesity
HK1121074A1 (en) Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione
WO2004021968A3 (en) Solution for ungual application
GB2430157A (en) Personal care products and methods for inhibiting the adherence of flora to skin
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2008009379A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
EP1935418A4 (en) COMPOSITION FOR ALLEVIATING FATIGUE SUBJECTIVE SYMPTOMS
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
WO2006054182A3 (en) Phosphoindoles as hiv inhibitors
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
MY140538A (en) Substituted n-acyl-2-aminothiazoles
WO2005053394A3 (de) Synergistische insektizide mischungen
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
WO2002017952A3 (en) Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
TW200640457A (en) Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes